Literature DB >> 10505313

Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution.

J Braier1, G Chantada, D Rosso, P Bernaldez, D Amaral, A Latella, B Balancini, A Masautis, J Goldberg.   

Abstract

The aim of this study was to retrospectively evaluate clinical characteristics at diagnosis and outcome of patients with Langerhans cell histiocytosis (LCH). From October 1987 to March 1996, 133 patients with confirmed LCH were admitted to Hospital JP Garrahan in Buenos Aires (123 evaluable). Median age was 5 years (range 15 days to 18 years). Initial organ involvement included bone 114 patients, ear 34, skin 30, liver 18, lung 14, lymph nodes 14, spleen 12, diabetes insipidus 9, and bone marrow 2. Nineteen patients had organ dysfunction, pulmonary 14, hematological 14, and hepatic 12. Two groups were defined: Group A included patients with single system disease (uni- or multifocal) and group B multisystem (with or without organ dysfunction). In group A (n = 82), 24 patients were treated with chemotherapy (prednisone and vinblastine), 21 with surgery, 15 received radiotherapy, and 22 were only observed. Patients of group B (n = 41) were treated with chemotherapy consisting of prednisone and vinblastine, DALHX 83, or LCH1-based chemotherapy. At a median follow-up of 3 years (range 1 month-8 5/12 years) 93% of patients of group A and 39% of group B survive free of reactivation. In group B, 22% had a reactivation and 39% died of progressive disease. Sequelae were detected in 35 patients (28%), which included diabetes insipidus in 17, hearing loss in 13, bony sequelae in 11, sclerosing cholangitis in 6, and lung fibrosis with bullae in 6. Two patients had a subsequent malignant disease. A total of 17 (14%) patients died and 16 of them belonged to the group B: 13 died of progressive disease, 2 due to sclerosing cholangitis (with sepsis in one case and encephalitis in the other one), 1 with progressive disease and associated myelofibrosis, and 1 patient of group A with active disease and brain stem tumor. Patients who had organ dysfunction had a reactivation free survival of 32%. All these patients survived with sequelae. Logistic regression analysis showed that organ dysfunction and hematological involvement had significant predictive values in relation to death. Patients of group A had an excellent survival rate, whereas in those of group B a high mortality was found, especially in the subgroup of patients with organ dysfunction. Lahey's criteria should be revised. Sequelae were also more common in this group.

Entities:  

Mesh:

Year:  1999        PMID: 10505313     DOI: 10.1080/088800199276921

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  13 in total

1.  Bone marrow findings at diagnosis in patients with multisystem langerhans cell histiocytosis.

Authors:  Maria Laura Galluzzo; Jorge Braier; Sergio D Rosenzweig; Maria T Garcia de Dávila; Diego Rosso
Journal:  Pediatr Dev Pathol       Date:  2010 Mar-Apr

2.  Evolving radiological features of hypothalamo-pituitary lesions in adult patients with Langerhans cell histiocytosis (LCH).

Authors:  P Makras; C Samara; M Antoniou; A Zetos; D Papadogias; Z Nikolakopoulou; E Andreakos; G Toloumis; G Kontogeorgos; G Piaditis; G A Kaltsas
Journal:  Neuroradiology       Date:  2005-11-15       Impact factor: 2.804

3.  Does adjunctive chemotherapy reduce remission rates compared to cortisone alone in unifocal or multifocal histiocytosis of bone?

Authors:  André Mathias Baptista; André Ferrari França Camargo; Olavo Pires de Camargo; Vicente Odone Filho; Alejandro Enzo Cassone
Journal:  Clin Orthop Relat Res       Date:  2012-03       Impact factor: 4.176

Review 4.  Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.

Authors:  Milen Minkov
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

Review 5.  Histiocytic disorders.

Authors:  Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen
Journal:  Nat Rev Dis Primers       Date:  2021-10-07       Impact factor: 65.038

6.  MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis.

Authors:  Daniela Prayer; Nicole Grois; Helmut Prosch; Helmut Gadner; Anthony J Barkovich
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

7.  Severe isolated pulmonary Langerhans cell histiocytosis in a 6-year-old girl.

Authors:  Johannes Schulze; Richard Kitz; Hans-Peter Grüttner; Helga Schmidt; Stefan Zielen
Journal:  Eur J Pediatr       Date:  2004-06       Impact factor: 3.183

8.  A Role for Angiogenesis in Canine Cutaneous Histiocytoma Regression: Insights into an Old Clinical Enigma.

Authors:  Diana Costa; Rita Ferreira; Justina Prada; Felisbina Luisa Queiroga; Paula Rodrigues; Filipe Silva; Isabel Pires
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

Review 9.  Langerhans cell histiocytosis.

Authors:  Joan Manel Gasent Blesa; Vicente Alberola Candel; Carlos Solano Vercet; Juan Laforga Canales; Christof Semler; Maria Rosa Pérez Antolí; Carlos Rodríguez-Galindo
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.340

Review 10.  Langerhans cell histiocytosis in adults: a case report and review of the literature.

Authors:  Cuihong Lian; Yuan Lu; Siyuan Shen
Journal:  Oncotarget       Date:  2016-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.